Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 123 The United Laboratories International Holdings Limited Annual Report 2024 33. SHARE-BASED PAYMENT TRANSACTIONS (Continued) Share award scheme (Continued) 2023 Weighted As at Granted Vested Lapsed Cancelled As at average fair 1 January during during during during 31 December value per Grantees Date of grant Vesting period 2023 the year the year the year the year 2023 award shares HK$ Directors Tsoi Hoi Shan 13 November 2023 13 November 2024 to 13 November 2026 – 575,100 – – – 575,100 7.45 Leung Wing Hon 13 November 2023 13 November 2024 to 13 November 2026 – 401,100 – – – 401,100 7.45 Choy Siu Chit 13 November 2023 13 November 2024 to 13 November 2026 – 268,800 – – – 268,800 7.45 Fang Yu Ping 13 November 2023 13 November 2024 to 13 November 2026 – 186,900 – – – 186,900 7.45 Zou Xian Hong 13 November 2023 13 November 2024 to 13 November 2026 – 186,900 – – – 186,900 7.45 Zhu Su Yan 13 November 2023 13 November 2024 to 13 November 2026 – 186,900 – – – 186,900 7.45 Other employees of the Group 13 November 2023 13 November 2024 to 13 November 2026 – 10,291,200 – – – 10,291,200 7.45 Total awarded shares granted 13 November 2023 13 November 2024 to 13 November 2026 – 12,096,900 – – – 12,096,900 7.45 Five highest paid individuals in aggregate 13 November 2023 13 November 2024 to 13 November 2026 – 1,618,800 – – – 1,618,800 7.45 The fair value of award share is determined based on the closing price of the Group’s publicly traded ordinary shares on the date of grant. The Group has to estimate the expected yearly percentage of grantees that will stay within the Group at the end of the vesting periods of the award share (the “Expected Retention Rate”) in order to determine the amount of share-based compensation expenses charged to profit or loss. As at 31 December 2024, the Expected Retention Rate for the Group’s directors and employees was assessed to be 100%. The total expenses recognised in the consolidated statement of profit or loss and other comprehensive income for share-based awards granted to the Group’s directors and employees are RMB7,069,000 and RMB40,295,000 for the year ended 31 December 2024, respectively (2023: RMB950,000 and RMB5,415,000). As at 31 December 2024, 169,605,750 (2023: 169,605,750) award shares are available for future grant under the aforementioned scheme mandate limit.